Clinical trials: Movement Abnormalities
Schizophrenia, Schizoaffective Disorder
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT05859698
- Testing
- Valbenazine
- Where
- 18 sites in United States
- Volunteers
- 59 people
- Sponsor
- Neurocrine Biosciences
Parkinson Disease
Pilot Study to Evaluate the Self-Management of Gait, Speech, and Dexterity Symptoms in Parkinson's Disease Using a Smartphone Application
The purpose of this study is to evaluate the impact of a smartphone application that delivers at-home therapy exercises on patients' self-management of gait, speech, and dexterity symptoms.
- Trial name
- NCT05120609
- Testing
- Parkinson's Application
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Beats Medical
Parkinson Disease
Pramipexole in Untreated and Levodopa-treated Parkinson's Disease Patients
The objectives of this study were to evaluate the efficacy, safety, and tolerability of pramipexole, as single-agent therapy or in combination with levodopa, in patients with Parkinson disease living in Hong Kong and Taiwan.
- Trial name
- NCT02177357
- Testing
- Pramipexole
- Volunteers
- 150 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease
Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of RO7568282 compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.
- Trial name
- TARBELA-PD (NCT07781644)
- Testing
- RO7568282
- Where
- 2 sites in United Kingdom
- Volunteers
- 474 people
- Sponsor
- Hoffmann-La Roche
Huntington Disease
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of MBF-015 in Huntington's Disease Patients
This is a Phase IIa (proof of concept), single center clinical trial to evaluate the safety and efficacy of daily MBF-015 oral treatment during 28 days in Huntington's Disease patients on top of standard of care.
- Trial name
- NCT06469853
- Testing
- MBF-015 16 mg oral capsules
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Medibiofarma S.L.
Chronic Troublesome Sialorrhea, Parkinson's Disease
Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions
The objective of this study is to investigate the efficacy and safety of two different dose levels of NT 201 (75 U or 100 U per cycle), compared with placebo, in reducing the salivary flow rate, and the severity and frequency of…
- Conditions
- Chronic Troublesome Sialorrhea, Parkinson's Disease, Post-stroke, Traumatic Brain Injury
- Trial name
- SIAXI (NCT02091739)
- Testing
- IncobotulinumtoxinA (100 Units), IncobotulinumtoxinA (75 Units)
- Where
- 31 sites in Germany, Poland
- Volunteers
- 184 people
- Sponsor
- Merz Pharmaceuticals GmbH
Parkinson Disease
A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease
This is a phase 2 study designed to assess the safety, tolerability and efficacy of NLY01 in subjects with early untreated Parkinson's disease (PD).
- Trial name
- NCT04154072
- Testing
- NLY01, Vehicle
- Where
- 61 sites in United States, Canada
- Volunteers
- 255 people
- Sponsor
- Neuraly, Inc.
Movement Disorders, Parkinson Disease
A Post-Market Study Evaluating the Safety of Infinity DBS System With MR Conditional Labeling
The Infinity MRI PMCF was conducted as an international, multicenter, observational, prospective, single-arm, post-market clinical follow-up (PMCF) study.
- Conditions
- Movement Disorders, Parkinson Disease, Essential Tremor, Tremor
- Trial name
- NCT03884231
- Testing
- Infinity DBS System with MR Conditional labelling
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 74 people
- Sponsor
- Abbott Medical Devices
Parkinson Disease
Quality-of-Life Index (Q-Index)
The main objective of this observational study is to use commonly-used connected objects (smartphones and smartwatches) to remotely assess and monitor the health-related quality of life (HrQoL) of people with Parkinson's disease…
- Trial name
- NCT06209502
- Where
- 4 sites in Belgium
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Koios Care
Akathisia, Drug-Induced, Antipsychotic Agents
Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)
This study is designed to evaluate the effectiveness of preladenant in the prevention (Part 1) or treatment (Part 2) of antipsychotic induced akathisia in participants with acute psychosis using the Barnes Akathisia Scale.
- Conditions
- Akathisia, Drug-Induced, Antipsychotic Agents, Movement Disorders
- Trial name
- NCT00693472
- Testing
- Preladenant, Anticholinergic agents or propanolol, Haloperidol
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease
REal-life ON PARKinson's - ITaly (REONPARK-IT)
The present study aims to evaluate the effectiveness and safety of opicapone in a real-world setting at centers for Parkinson's disease located in Italy.
- Trial name
- NCT07403799
- Testing
- Opicapone 50 mg
- Where
- 20 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
Study J3Z-MC-OJAA is a Phase 1/2a, multicenter, open-label, ascending dose, first in-human study that will evaluate the safety of intracisternal LY3884961 administration in patients with moderate to severe Parkinson's disease…
- Trial name
- NCT04127578
- Testing
- LY3884961, Methylprednisolone, Sirolimus
- Where
- 15 sites in United States, Israel
- Volunteers
- 32 people
- Sponsor
- Prevail Therapeutics
Parkinson Disease
A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients
A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients
- Trial name
- NCT04629404
- Testing
- LY03003
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Luye Pharma Group Ltd.
Parkinson Disease
Development of Digital Diagnostic Devices for Parkinson's Disease
In this project, ocular motor, pupil and gait data in people with Parkinson's disease (PD) will be collected in order to develop machine learning models for the diagnosis and monitoring of PD.
- Trial name
- NCT06663826
- Testing
- oculomotor and pupillary function assessment
- Where
- Switzerland
- Volunteers
- 116 people
- Sponsor
- machineMD AG
Essential Tremor
T2000 in Essential Tremor - Open Label Continuation
This study will evaluate the safety and efficacy of T2000 when used to treat patients with moderate to severe essential tremor over an 18 month period.
- Trial name
- NCT00655278
- Testing
- T2000
- Where
- 3 sites in Canada
- Volunteers
- 5 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Multiple System Atrophy
A Study of Lu AF82422 in Participants With Multiple System Atrophy
To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.
- Trial name
- AMULET (NCT05104476)
- Testing
- Lu AF82422
- Where
- 19 sites in United States, Japan
- Volunteers
- 64 people
- Sponsor
- H. Lundbeck A/S
Parkinson's Disease
Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study
The purpose of the study is to evaluate the effectiveness of the Medtronic Adaptive DBS therapy (aDBS) for Parkinson's Disease in China with the Percept family of Implantable Neurostimulators (Percept PC and Percept RC).
- Trial name
- NCT07216976
- Testing
- Percept™ PC and Percept RC with Adaptive DBS (aDBS™)
- Where
- 5 sites in China
- Volunteers
- 61 people
- Sponsor
- MedtronicNeuro
Parkinson's Disease
Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease
To study the profile of Neupro patch administrated at 2 mg, 4 mg, 6 mg and 8 mg/day weekly in patients with early-stage Parkinson's disease
- Trial name
- NCT02728947
- Testing
- ROTIGOTINE
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Luye Pharma Group Ltd.
Parkinson Disease
Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Disease
Observational cross-sectional study in PD patients and healthy controls (HC) using an investigational medical device consisting of a passive small intestine microbiome aspiration (SIMBA) system (capsule) that is ingested orally…
- Trial name
- SmIle (NCT06003608)
- Testing
- Fluid biopsy capsule, Levodopa-Carbidopa Immediate Release
- Where
- Canada
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Nimble Science Ltd.
Parkinson Disease
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa…
- Trial name
- NCT07432958
- Testing
- AP-472
- Where
- 30 sites in United States
- Volunteers
- 150 people
- Sponsor
- Appello Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.